GSK报告,2024年收入为31.4B英镑,预计2025年将有五大药物批准,艾滋病毒、癌症和呼吸道治疗不断取得进展。 GSK reports £31.4B in 2024 revenue, with five major drug approvals expected in 2025 and ongoing advances in HIV, cancer, and respiratory treatments.

GSK正在通过创新疗法和研究促进全球健康,在长效艾滋病毒治疗、癌症免疫疗法和呼吸道疾病生物学方面取得突破。 GSK is advancing global health through innovative therapies and research, with breakthroughs in long-acting HIV treatments, cancer immunotherapies, and respiratory disease biologics. 该公司的《非洲开放实验室倡议》加强了撒哈拉以南非洲的科学能力,而数字生物双胞胎和有机体使个人化癌症护理成为可能。 The company’s Africa Open Lab initiative strengthens scientific capacity in sub-Saharan Africa, while digital biological twins and organoids are enabling personalized cancer care. GSK报告说,2024年的营业额为314亿英镑,预计2025年将有71个输油管候选人和5个主要产品批准,这反映出它致力于在所有关键疾病领域进行以病人为中心的可持续创新。 GSK reported £31.4 billion in turnover in 2024, with 71 pipeline candidates and five major product approvals expected in 2025, reflecting its commitment to sustainable, patient-centered innovation across key disease areas.